For US residents only.

Understanding Treatment

KISQALI® (ribociclib) + HORMONE THERAPY

Understanding Treatment Understanding Treatment

Metastatic Breast Cancer Treatment With KISQALI

KISQALI® (ribociclib) is a prescription medicine that's taken with hormone therapy to treat postmenopausal women who are living with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer.

KISQALI and Hormone Therapy Work Together

To understand how KISQALI works with hormone therapy, it’s important to also understand the role that hormones play in causing your type of cancer cells to grow and divide.

 

Together, KISQALI and hormone therapy work to help delay disease progression:

  • KISQALI is a targeted treatment that blocks, or interferes with, substances that play a role in cancer cell growth. KISQALI can also affect healthy cells
  • Hormone therapy works by stopping or reducing the production of hormones, like estrogen
  • Hormones, like estrogen, activate CDK4/6 proteins, leading to cell division and tumor growth

 

Click here to learn more about results with KISQALI.

 

Watch the video below to get a better understanding of how KISQALI® (ribociclib) and hormone therapy work together to help delay the progression of HR+, HER2- metastatic breast cancer.

How KISQALI Works
How KISQALI Works